U.S. approves GSK's purchase of Novartis vaccine business: companies

Borderless Insights

How to impress the headhunter: Andrew Kris in conversation with Anthony Harling provide the clues.

Now performing in the biotech big top: The Chief Medical Officer

What can the Life Sciences sector and other industries learn from Amazon

U.S. approves GSK’s purchase of Novartis vaccine business: companies

November 27, 2014

Life sciences

(Reuters) – GlaxoSmithKline won U.S. antitrust approval to buy Novartis AG’s vaccine business, with the exception of influenza vaccines, the two companies said on Wednesday.

The deal is part of a three-way transaction unveiled in April, which includes Britain’s GSK buying the vaccines business of Novartis, the Swiss company purchasing GSK’s cancer drugs, and the two groups tying up in consumer healthcare.

The U.S. Federal Trade Commission had previously announced on Wednesday that it approved the consumer health care joint venture on the condition that Novartis sell its Habitrol nicotine patch.

Novartis and Glaxo, which has Nicoderm CQ, are two of only three companies that sell nicotine patches to U.S. retailers, the FTC said.

(Reporting by Diane Bartz; Editing by Diane Craft)

Sector News

Categories

Borderless Insights

U.S. approves GSK’s purchase of Novartis vaccine business: companies

Related News

Genentech aims high with new diversity goals, including doubling hires and spending $1B with diverse suppliers

Merck CEO Frazier joins army of Black execs speaking out on restrictive voting-rights laws

Zimmer Biomet bundles robotic surgery, apps and digital health programs into one orthopedics package

Global Hub

Phone

E-mail

Services

Sectors

Find out more